Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform
Summary
Vandria emerges from stealth announcing its $20.6M (CHF18M) Series A financing led by ND Capital Lead candidate VNA-318 is a clinic-ready, brain- penetrant, mitophagy inducer shown to improve memory and learning Potential for a range of CNS indications including cognitive impairment, dementia, Alzheimers and Parkinsons Disease Wider portfolio of mitophagy inducers addresses other age-related and chronic diseases of muscle, lung and liver Management team includes CEO Klaus Dugi, CSO Penelope Andreux and Head of BD & Finance Peter Harboe-Schmidt. Patrick Aebischer chairs the board.Lausanne, Switzerland 14 December 2023 Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today emerged from stealth with the announcement of its successful Series A fundraise. Capitalizing on 15 years of discovery science, Vandria has rapidly developed its platform and portfolio, and its lead program, VNA-318, a patent-protected, brain-penetrant, first-in-class mitophagy inducer, is on track to enter clinical trials in Europe in Q2 2024.The companys impressive management team includes senior pharma executive Klaus Dugi, MD as CEO, mitochondrial expert Penelope Andreux, PhD as CSO, and life sciences entrepreneur Peter Harboe-Schmidt, MSc, MBA, as Head of BD & Finance.Penelope Andreux, CSO of Vandria, said: The potential of mitophagy as a new therapeutic approach for tackling CNS disorders is increasingly recognised by the pharmaceutical industry. We believe it has the potential to impact a range of CNS indications and we look forward to starting clinical development in 2024.Klaus Dugi, CEO of Vandria, said: ND Capital has been a highly supportive investor through our startup phase and our Series A financing. 2024 will be a transformative year for Vandria as it becomes a clinical stage company with a novel small molecule designed to address cognitive impairment and neurodegeneration - areas of critical patient need in an aging world population.